Rossari Biotech News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Rossari Biotech Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Rossari Biotech Ltd.
Rating: 5
Author: Deven Choksey

Keep track of all breaking news and updates on Rossari Biotech from all sources in a single place.

Rossari Biotech Ltd.

29 May 2026

528.25

-2.83%

Company Update

Rossari Biotech Ltd - 543213 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Report for the Financial Year 2025-26.

pdf

Rossari Biotech Ltd.

27 May 2026

528.25

-2.83%

Company Update

Rossari Biotech Ltd - 543213 - Intimation Of Grant Of Options Under Rossari Employee Stock Option …

BSE India

Intimation of grant of 830050 options under Rossari Employee Stock Option Plan- 2019.

pdf

Rossari Biotech Ltd.

27 May 2026

528.25

-2.83%

Company Update

Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Re-appointment of Ms. Esha Padmanabhan Achan (DIN:10350369), as a Non-Executive Independent Director of the Company.

pdf

Rossari Biotech Ltd.

27 May 2026

528.25

-2.83%

Corp. Note

Rossari Biotech Ltd - 543213 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Outcome of Board Meeting held on May 27, 2026

pdf

Rossari Biotech Ltd.

21 May 2026

528.25

-2.83%

Company Update

Rossari Biotech Ltd - 543213 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

pdf

Rossari Biotech Ltd.

04 May 2026

528.25

-2.83%

Earnings Call

Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Intimation of Transcript of Q4 FY 26 for the Earnings Conference Call held on April 28, 2026.

pdf

Rossari Biotech Ltd.

30 Apr 2026

528.25

-2.83%

Result Update

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech closed FY26 on a strong footing, reporting its highest-ever quarterly revenue and EBITDA in Q4, with consolidated revenue from operations for the full year at INR 2,396.4 crore up 15% YoY, driven primarily by volume.

Rossari Biotech Ltd. has an average target of 587.00 from 2 brokers.

Rossari Biotech Ltd.

29 Apr 2026

528.25

-2.83%

Focus on profitable growth, improved utilisation and sale of non-core assets in FY27

Buy: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari’s Q4 EBITDA grew 11.2% YoY, while gross/EBITDA margins shrank QoQ due to inferior mix. Rossari has outlined its focus areas for FY27. Grow profitably by improving sales in the high-margin categories of pharma, aroma and personal care; separately, the company plans to exit its low-margin B2C business.

Rossari Biotech Ltd. is trading below its 150 day SMA of 535.3

Rossari Biotech Ltd.

28 Apr 2026

528.25

-2.83%

Company Update

Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Cessation

BSE India

Intimation of completion of tenure of Ms. Aparna Sharma (DIN:07132341) as an Independent Director of the Company from the close of business hours of April 28, 2026.

pdf